biotech / news / / The Manila Times
Sanofi’s Cenrifki (tolebrutinib) recommended for EU approval by the CHMP to treat secondary progressive multiple sclerosis.
CHMP has recommended EU approval of Sanofi’s Cenrifki (tolebrutinib) for non-relapsing SPMS.
KEY POINTS
- The HERCULES phase 3 study showed Cenrifki significantly delayed disability progression in non-relapsing SPMS.
- Safety data identifies drug-induced liver injury as a known risk of Cenrifki requiring strict liver monitoring.
- Cenrifki targets smoldering neuroinflammation, a key driver of disability in secondary progressive MS.
- Cenrifki submissions are under review with regulatory authorities in multiple countries beyond the EU.
COMPANIES
Summarized by Newsio from The Manila Times. How we summarize →